<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01186445</url>
  </required_header>
  <id_info>
    <org_study_id>MIAMI-2008-09</org_study_id>
    <nct_id>NCT01186445</nct_id>
  </id_info>
  <brief_title>Morphine In Acute Myocardial Infarction</brief_title>
  <acronym>MIAMI</acronym>
  <official_title>Evaluation of the Cardioprotective Effect of Intracoronary Injection of Morphine During Reperfusion in Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French Cardiology Society</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>French Cardiology Society</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether intracoronary injection of morphine
      chlorhydrate is effective to limit ischemia-reperfusion lesion during percutaneous coronary
      angioplasty in patients with acute myocardial infarction (AMI).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infarct size evaluated by delayed enhancement-magnetic resonance imaging</measure>
    <time_frame>between day 3 and day 5 after acute myocardial infarction (AMI)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infarct size/area at risk ratio evaluated by MRI</measure>
    <time_frame>between day 3 and day 5 after AMI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>release of creatine kinase (CK) and troponin I (TnI) during reperfusion</measure>
    <time_frame>during the first 72 hours after reperfusion</time_frame>
    <description>The Area Under the Curve of CK and TnI during reperfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Thrombolysis In Myocardial Infarction (TIMI) myocardial Blush after reperfusion</measure>
    <time_frame>at day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ST segment resolution after reperfusion</measure>
    <time_frame>during the first 24 hours after reperfusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Ejection Fraction measured by echocardiography</measure>
    <time_frame>at day 1 and day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infarct size measurement by delayed enhancement-magnetic resonance imaging</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Morphine chlorhydrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intracoronary injection of morphine chlorhydrate during reperfusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intracoronary injection of saline solution during reperfusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>morphine chlorhydrate</intervention_name>
    <description>1mg of morphine chlorhydrate dilute in 3ml of saline solution, intracoronary injection, just before reperfusion</description>
    <arm_group_label>Morphine chlorhydrate</arm_group_label>
    <other_name>Morphine Chlorhydrate Lavoisier</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline solution</intervention_name>
    <description>3 ml of saline solution , intracoronary injection during reperfusion</description>
    <arm_group_label>Saline solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Acute Myocardial Infarction less than 6 hours defined by

               1. prolonged chest pain (&gt;15 min)

               2. in association with

                    -  ST elevation 1mm or more in two contiguous leads

                    -  or occurence of Q wave in three contiguous leads

                    -  or occurence of left bundle branch block

          2. Culprit lesion eligible for percutaneous coronary intervention (PCI)

          3. TIMI flow 0 before PCI

        Exclusion Criteria:

          1. Fibrinolysis

          2. Allergy to morphine

          3. Active epilepsy

          4. Brain injury or intracranial hypertension

          5. Previous AMI, coronary artery bypass graft (CABG)

          6. Cardiac arrest

          7. Cardiogenic shock, significant mitral regurgitation or intraventricular communication
             at inclusion

          8. Mechanical ventilation at inclusion

          9. Significant ventricular arrhythmia or atrioventricular block type II or III at
             inclusion

         10. Decompensated chronic obstructive pulmonary disease at inclusion

         11. chronic hepatocellular failure

         12. MRI contraindications

         13. Gadolinium chelates injection contraindications

         14. Current treatment with morphine chlorhydrate, buprenorphine, nalbuphine, pentazocine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Lecorvoisier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henri Mondor Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Henri Mondor Hospital</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Marie Lannelongue</name>
      <address>
        <city>Plessis Robinson</city>
        <zip>92350</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2010</study_first_submitted>
  <study_first_submitted_qc>August 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2010</study_first_posted>
  <last_update_submitted>February 3, 2017</last_update_submitted>
  <last_update_submitted_qc>February 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myocardial Infarction</keyword>
  <keyword>Cardioprotective effect</keyword>
  <keyword>Pharmacological postconditioning</keyword>
  <keyword>Morphine Chlorhydrate</keyword>
  <keyword>Cardiac MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

